Remibrutinib is an Orally Active BTK Inhibitor for the Chronic Urticaria Treatment
Chronic urticaria is a heterogeneous, persistent, and severely debilitating disease. Bruton’s tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic signaling. Especially, BTK is critical…
